144 related articles for article (PubMed ID: 27001209)
1. Hormone receptor positive, HER2 negative metastatic breast cancer: Future treatment landscape.
Redfern A; Burslem K; Woodward N; Beith J; McCarthy N; De Boer R; Bell R
Asia Pac J Clin Oncol; 2016 Mar; 12 Suppl 1():19-31. PubMed ID: 27001209
[TBL] [Abstract][Full Text] [Related]
2. Hormone receptor positive, HER2 negative metastatic breast cancer: A systematic review of the current treatment landscape.
Beith J; Burslem K; Bell R; Woodward N; McCarthy N; De Boer R; Loi S; Redfern A
Asia Pac J Clin Oncol; 2016 Mar; 12 Suppl 1():3-18. PubMed ID: 27001208
[TBL] [Abstract][Full Text] [Related]
3. [Advanced luminal breast cancer (hormone receptor-positive, HER2 negative): New therapeutic options in 2015].
Vanacker H; Bally O; Kassem L; Tredan O; Heudel P; Bachelot T
Bull Cancer; 2015 Jun; 102(6 Suppl 1):S47-52. PubMed ID: 26118876
[TBL] [Abstract][Full Text] [Related]
4. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
5. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.
Shah AN; Cristofanilli M
Curr Treat Options Oncol; 2017 Jan; 18(1):6. PubMed ID: 28197838
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer.
Fedele P; Orlando L; Schiavone P; Calvani N; Caliolo C; Quaranta A; Nacci A; Cinieri S
Crit Rev Oncol Hematol; 2015 Jun; 94(3):291-301. PubMed ID: 25624176
[TBL] [Abstract][Full Text] [Related]
7. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
8. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
9. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
[TBL] [Abstract][Full Text] [Related]
10. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
11. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
[TBL] [Abstract][Full Text] [Related]
12. Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer.
Yu KD; Jiang YZ; Hao S; Shao ZM
BMC Med; 2015 Oct; 13():254. PubMed ID: 26437901
[TBL] [Abstract][Full Text] [Related]
13. Endocrine therapy and strategies to overcome therapeutic resistance in breast cancer.
Mancuso MR; Massarweh SA
Curr Probl Cancer; 2016; 40(2-4):95-105. PubMed ID: 27839747
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
Johnston S; Pippen J; Pivot X; Lichinitser M; Sadeghi S; Dieras V; Gomez HL; Romieu G; Manikhas A; Kennedy MJ; Press MF; Maltzman J; Florance A; O'Rourke L; Oliva C; Stein S; Pegram M
J Clin Oncol; 2009 Nov; 27(33):5538-46. PubMed ID: 19786658
[TBL] [Abstract][Full Text] [Related]
15. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going.
Schettini F; Buono G; Cardalesi C; Desideri I; De Placido S; Del Mastro L
Cancer Treat Rev; 2016 May; 46():20-6. PubMed ID: 27057657
[TBL] [Abstract][Full Text] [Related]
16. From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?
Wu VS; Kanaya N; Lo C; Mortimer J; Chen S
J Steroid Biochem Mol Biol; 2015 Sep; 153():45-53. PubMed ID: 25998416
[TBL] [Abstract][Full Text] [Related]
17. The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer.
Boscolo Bielo L; Trapani D; Nicolò E; Valenza C; Guidi L; Belli C; Kotteas E; Marra A; Prat A; Fusco N; Criscitiello C; Burstein HJ; Curigliano G
Cancer Treat Rev; 2024 Jul; 128():102761. PubMed ID: 38772169
[TBL] [Abstract][Full Text] [Related]
18. Endocrine therapy for ER-positive/HER2-negative metastatic breast cancer.
Reinert T; de Paula B; Shafaee MN; Souza PH; Ellis MJ; Bines J
Chin Clin Oncol; 2018 Jun; 7(3):25. PubMed ID: 30056727
[TBL] [Abstract][Full Text] [Related]
19. ICON 2013: practical consensus recommendations for hormone receptor-positive Her2-negative advanced or metastatic breastcancer.
Parikh PM; Gupta S; Dawood S; Rugo H; Bhattacharyya GS; Agarwal A; Chacko R; Sahoo TP; Babu G; Agarwal S; Munshi A; Goswami C; Smruti BK; Bondarde S; Desai C; Rajappa S; Somani N; Singh M; Nimmagadda R; Pavitran K; Mehta A; Parmar V; Desai S; Nair R; Doval D
Indian J Cancer; 2014; 51(1):73-9. PubMed ID: 24947101
[TBL] [Abstract][Full Text] [Related]
20. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
